First Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction Technology

STAMFORD, Conn--(BUSINESS WIRE)--TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today the treatment of the initial patient for its first-in-human clinical trial evaluating the company's groundbreaking quantitative corneal crosslinking (qCXL™) technology for non-invasive refractive vision correction. The study marks a significant milestone in the development of the first vision correction platform designed to strengthen rather than compromise corneal integrity. The